Results
recurrence/metastatic disease, Twenty‐nine, toxicities
CPS, DISEASE
Thirty‐seven patients completed the preoperative treatment. Twenty‐nine patients had curative R0 resection. 6/29 (21%; 95% CI: 0.08–0.40) achieved ypCR with TRS 0 in resected patients. 26/29 (90%; 95% CI: 0.73–0.98) had ypRR with TRS ≤2. Twenty‐six patients finished adjuvant therapy with a median 36.3‐month follow‐up. Three patients had recurrence/metastatic disease (at 9‐, 10‐, 22 months enrollment) with one dead at 23 months, and two are still alive at 28 and 36.5 months. The remaining (23/26) are free of disease with 3 years DFS of 88.5% and 3 years OS of 92.3%. There were no unexpected toxicities. Preoperative ICI + chemotherapy enhanced immune responses significantly with increasing expression of PD‐L1 (CPS ≥10, 